Russian Heart Failure Journal 2011year Use of biological markers in diagnosis of diastolic heart failure

To access this material please log in or register

Register Authorize

Use of biological markers in diagnosis of diastolic heart failure

Drapkina O. M., Dubolazova Yu. V.
State Budgetary Educational Institution “I. M. Sechenov First Moscow State Medical University” of the RF Ministry of Health Care, Trubetskaya 8, Bld. 2, Moscow 119991

Keywords: biological markers, diagnosis, diastolic CHF

DOI: 10.18087/rhfj.2011.6.1583

The researches devoted to possibility of administration of natriuretic peptides and helactin-3 as HF diagnostic and prognostic markers are analyzed in the review.
  1. Smiseth OA, Tendera M. Diastolic heart failure. – London: Springer-Verlag; 2008. – 349 р.
  2. Mottram PM, Marwick TH. Assessment of diastolic function: what the general cardiologist needs to know. Heart. 2005;91 (5):681–695.
  3. Mark DB, Felker GM. B-type natriuretic peptide – a biomarker for all seasons? N Engl J Med. 2004;350 (7):718–720.
  4. McCullough PA, Nowak RM, McCord J et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002;106 (4):416–422.
  5. Maisel AS, McCord J, Nowak RM et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol. 2003;41 (11):2010–2017.
  6. Dokainish H, Zoghbi W, Lakkis N et al. Optimal noninvasive assessment of left ventricular filling pressures: a comparison of tissue Doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters. Circulation. 2004;109 (20):2432–2439.
  7. Yamamoto K, Burnett JC Jr, Jougasaki M et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996;28 (6):988–994.
  8. Wright SP, Prickett TC, Doughty RN et al. Amino-terminal pro-C-type natriuretic peptide in heart failure. Hypertension. 2004;43 (1):94–100.
  9. Luchner A, Hengstenberg C, Löwel H et al. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension. 2005;46 (1):118–123.
  10. Wang TJ, Larson MG, Levy D et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109 (5):594–600.
  11. Das SR, Drazner MH, Dries DL et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation. 2005;112 (14):2163–2168.
  12. Bibbins-Domingo K, Ansari M, Schiller N et al. B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study. Circulation. 2003;108 (24):2987–2992.
  13. Lubien E, DeMaria A, Krishnaswamy P et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction. Comparison with Doppler velocity recordings. Circulation. 2002;105 (5):595–601.
  14. Senni M, Tribouilloy CM; Rodeheffer R J et all. Congestive Heart Failure in the Community. A Study of All Incident Cases in Olmsted County, Minnesota, in 1991 Circulation. 1998;98 (21):2282–2289.
  15. Lukowicz TV, Fischer M, Hense HW et al. BNP as a marker of diastolic dysfunction in the general population: importance of left ventricular hypertrophy. Eur J Heart Fail. 2005;7 (4):525–531.
  16. Tschope C, Kasner M, Westermann D et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J. 2005;26 (21):2277–2284.
  17. Yamaguchi H, Yoshida K, Sakata Y. Elevation of plasma brain natriuretic peptide is a hallmark of diastolic heart failure independent of ventricular hypertrophy. J Am Coll Cardiol. 2004;43 (1):55–60.
  18. Rousseau MF, Gurné O, Duprez D et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J Am Coll Cardiol. 2002;40 (9):1596–1601.
  19. Latini R, Masson S, Anand I et al; for the Val-HeFT Investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure. Circulation. 2002;106 (19):2454–2458.
  20. Dickstein K, Cohen-Solal A, Filippatos G et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29 (19):2388–2442.
  21. Национальные клинические рекомендации. Сборник. Под ред. Оганова Р. Г., 2‑е издание. – М.: Изд-во «Силицея-Полиграф», 2009. – 528 с.
  22. Lok DJ, Van Der Meer P, de la Porte PW et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99 (5):323–328.
  23. Felker GM, Fiuzat M, Shaw LK et al. Prognostic value of galectin-3 in chronic heart failure: results from the HF-ACTION study. Eur Heart J. 2010;31 (1):429.
  24. Jaarsma T, van der Wal MH, Lesman-Leegte I et al; Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH) Investigators. Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). Arch Intern Med. 2008;168 (3):316–324.
  25. Lin YH, Lin LY, Wu YW et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta. 2009;409 (1-2):96–99.
Drapkina O.M., Dubolazova Yu.V. Use of biological markers in diagnosis of diastolic heart failure. Russian Heart Failure Journal. 2011;12(6):364-372.

To access this material please log in or register

Register Authorize
Ru En